The global arthralgia management market garnered a market value of US$ 5.95 billion in 2022 and is expected to accumulate a market value of US$ 15.5 billion by registering a CAGR of 9.1% in the forecast period 2023 to 2033. Growth of the arthralgia management market can be attributed to increasing number of individuals are looking for efficient remedies to manage this ailment. The market for arthralgia management registered a CAGR of 5.3% in the historical period 2018 to 2022
Arthralgia management refers to the medical care and treatment provided to individuals experiencing joint pain or arthralgia. Arthralgia is a common symptom of many different conditions, including arthritis, lupus, fibromyalgia, and other autoimmune diseases.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 6.49 billion |
| Anticipated Forecast Value (2033) | US$ 15.5 billion |
| Projected Growth Rate (2023 to 2033) | 9.1% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Arthralgia management reflected a value of 5.3% during the historical period, 2018 to 2022. The growth of the arthralgia management market is being driven by several factors, including the increasing prevalence of arthritis and related conditions, the aging population, rising healthcare expenditure, and advancements in medical technology. In addition, there is growing awareness about joint health and the importance of managing arthralgia symptoms, which is also contributing to market growth.
The market for arthralgia management products and services is diverse and includes a wide range of products, such as prescription medications, over-the-counter pain relievers, topical creams, supplements, and medical devices. In addition, there is a growing trend towards holistic and alternative therapies such as acupuncture, chiropractic, and massage therapy. Thus, the market for arthralgia management is expected to register a CAGR of 9.1% in the forecast period 2023 to 2033.
Advancements in arthralgia management products spurring market growth for Arthralgia management
Arthritis is a common cause of joint pain, and its prevalence is increasing worldwide due to aging populations, unhealthy lifestyles, and other factors. As a result, the demand for arthralgia management products and services is also increasing.
Many people are becoming more aware of the importance of joint health and are taking proactive steps to manage joint pain. This includes regular exercise, a healthy diet, and the use of arthralgia management products such as supplements, pain relievers, and topical creams.
The development of new and more effective arthralgia management products is driving growth in the market. This includes novel drug therapies, innovative medical devices, and advanced diagnostic tools. As healthcare spending continues to rise globally, more resources are being allocated to the management of chronic conditions such as arthritis. This has led to increased investment in research and development of arthralgia management products and services.
As the global population ages, the incidence of joint pain and related conditions such as arthritis is expected to increase. This is driving demand for arthralgia management products and services tailored to the needs of older adults.
Availability of treatment options shaping landscape for arthralgia management market
Medication: Nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids may be prescribed to relieve joint pain and inflammation. Disease-modifying antirheumatic drugs (DMARDs) may also be used to treat underlying autoimmune conditions.
Lifestyle modifications: Exercise, physical therapy, and weight management may be recommended to improve joint flexibility, reduce pain, and prevent further joint damage.
Alternative therapies: Acupuncture, massage therapy, and dietary supplements may be used to complement traditional medical treatment.
Surgical intervention: In severe cases, surgery may be necessary to repair damaged joints or replace them with artificial joints.
Principal Consultant
Lack of awareness and challenges with regulatory approvals derailing market growth for arthralgia management market
Many of the current treatments for arthralgia, such as nonsteroidal anti-inflammatory drugs (NSAIDs), have limited efficacy and can have side effects. This has led to a need for more effective and safer treatments. Arthralgia management products and services can be expensive, particularly for those without insurance coverage. This can limit access to treatment for some patients.
While awareness about joint health is increasing, there is still a lack of awareness among many individuals about the available treatment options for arthralgia. This can lead to delayed diagnosis and treatment. Developing new arthralgia management products and bringing them to market can be a lengthy and costly process due to regulatory requirements. This can limit innovation in the industry.
Many individuals with arthralgia seek alternative therapies such as acupuncture, chiropractic, or herbal remedies. This can limit demand for traditional arthralgia management products and services.
Advancements in medical technology driving growth of Arthralgia management market
The arthralgia management market in North America is expected to continue to grow in the coming years. North America has a high prevalence of arthralgia and related conditions such as arthritis, and this is driving demand for arthralgia management products and services in the region.
The United States is the largest market for arthralgia management in North America, accounting for the majority of the region's market share. The market is also growing in Canada and Mexico, although at a slower pace than in the United States.
Some of the key drivers of the arthralgia management market in North America include the aging population, rising healthcare expenditure, and advancements in medical technology. In addition, there is increasing awareness about joint health and the importance of managing arthralgia symptoms.
The market for arthralgia management products and services in North America is diverse and includes a wide range of products, such as prescription medications, over-the-counter pain relievers, topical creams, supplements, and medical devices. In addition, there is a growing trend towards holistic and alternative therapies such as acupuncture, chiropractic, and massage therapy. Thus, owing to the aforementioned reasons, North America is expected to hold 43% market share for arthralgia management market in 2023.
High prevalence of arthritis boosting arthralgia management market growth in Europe
The arthralgia management market in Europe is also expected to continue to grow in the coming years. Europe has a high prevalence of arthritis and related conditions, and this is driving demand for arthralgia management products and services in the region.
The market for arthralgia management in Europe is diverse and includes a wide range of products, such as prescription medications, over-the-counter pain relievers, topical creams, supplements, and medical devices. In addition, there is a growing trend towards holistic and alternative therapies such as acupuncture, chiropractic, and massage therapy.
The United Kingdom, Germany, France, Italy, and Spain are the largest markets for arthralgia management in Europe, accounting for the majority of the region's market share. The market is also growing in other European countries, although at a slower pace than in these major markets. Thus, Europe is expected to hold 41% market share for arthralgia management market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Effective nature of NSAIDs increasing dependency for management of arthralgia
NSAIDs are often used for arthralgia management because they are effective at reducing pain, inflammation, and fever. They work by inhibiting the production of prostaglandins, which are responsible for causing inflammation and pain in the body. NSAIDs are widely available and can be purchased over-the-counter, making them a convenient option for many patients.
Additionally, NSAIDs are generally well-tolerated by most patients when taken as directed. They are available in a variety of formulations, including oral tablets, capsules, and liquids, as well as topical creams and gels that can be applied directly to the affected joint. This makes it easier for patients to find a formulation that works well for them. Thus, by drug class, NSAIDs are expected to possess 40% market share for arthralgia management market in 2023.
Key players in the arthralgia management market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Boehringer Ingelheim International GmbH, AstraZeneca, Johnson & Johnson Private Limited, Merck & Co., Inc., Hoffmann-La Roche Ltd. and Bristol-Myers Squibb Company
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 6.49 billion |
| Market Value in 2033 | US$ 15.5 billion |
| Growth Rate | CAGR of 9.1% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
From 2018 to 2022, the market registered a CAGR of 5.3%.
The global market is estimated to reach US$ 15.5 billion by 2033.
The hospital pharmacies hold high revenue potential.
The United States, Canada and Mexico dominate the global market.
The market is forecast to register a CAGR of 9.1% through 2033.
1. Executive Summary | Arthralgia Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. NSAID
5.3.2. Corticosteroids
5.3.3. Antidepressants
5.3.4. Anticonvulsants
5.3.5. Antibiotics
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Knee and Ankle Pain
6.3.2. Hip Pain
6.3.3. Shoulder and Elbow Pain
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Application
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Application
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Application
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Application
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. United Kingdom
11.2.1.2. Spain
11.2.1.3. Germany
11.2.1.4. Italy
11.2.1.5. France
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Application
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Application
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. India
12.2.1.4. South Korea
12.2.1.5. Rest of Asia Pacific
12.2.2. By Drug Class
12.2.3. By Application
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Application
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. South Africa
13.2.1.2. GCC Countries
13.2.1.3. Rest of Middle East and Africa
13.2.2. By Drug Class
13.2.3. By Application
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Application
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Class
14.1.2.2. By Application
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Class
14.2.2.2. By Application
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Class
14.3.2.2. By Application
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Class
14.4.2.2. By Application
14.4.2.3. By Distribution Channel
14.5. U.K.
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Class
14.5.2.2. By Application
14.5.2.3. By Distribution Channel
14.6. Spain
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Class
14.6.2.2. By Application
14.6.2.3. By Distribution Channel
14.7. Germany
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Class
14.7.2.2. By Application
14.7.2.3. By Distribution Channel
14.8. Italy
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Class
14.8.2.2. By Application
14.8.2.3. By Distribution Channel
14.9. France
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Class
14.9.2.2. By Application
14.9.2.3. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Class
14.10.2.2. By Application
14.10.2.3. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Class
14.11.2.2. By Application
14.11.2.3. By Distribution Channel
14.12. India
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Class
14.12.2.2. By Application
14.12.2.3. By Distribution Channel
14.13. South Korea
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Class
14.13.2.2. By Application
14.13.2.3. By Distribution Channel
14.14. South Africa
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Class
14.14.2.2. By Application
14.14.2.3. By Distribution Channel
14.15. GCC Countries
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Class
14.15.2.2. By Application
14.15.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class
15.3.3. By Application
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Pfizer Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. GlaxoSmithKline plc
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Novartis AG
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Mylan N.V.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Teva Pharmaceutical Industries Ltd.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Sanofi
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Boehringer Ingelheim International GmbH
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. AstraZeneca
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Johnson & Johnson Private Limited
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Merck & Co., Inc.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. F. Hoffmann-La Roche Ltd.
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.12. Bristol-Myers Squibb Company
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Arthralgia Management Market
